Vima LLC’s Neurocrine Biosciences NBIX Stock Holding History

Vima LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$10.1K	–	251
2024 Q1	$10.1K	Hold	100	–	–	0.01%	232
2023 Q4	$13.2K	Buy	+100	New	+$11.5K	0.03%	228

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vima LLC's NBIX Position: Q2 2024 in Review

Vima LLC sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 100 shares — an estimated $10.1K sold.

Vima LLC first reported a position in NBIX in Q4 2023 and held it in 2 quarters. The position peaked at $13.2K in Q4 2023. 595 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

Vima LLC reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
Vima LLC sold 100 Neurocrine Biosciences shares in Q2 2024, an estimated $10.1K.
Vima LLC first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 2 quarters.
Vima LLC's Neurocrine Biosciences position peaked at $13.2K in Q4 2023.
595 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Vima LLC's 13F filing for Q2 2024, filed 8 Aug 2024.